FOLD Insider Trading

Insider Ownership Percentage: 2.20%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $645,262.50

Amicus Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Amicus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Amicus Therapeutics Share Price & Price History

Current Price: $7.68
Price Change: Price Increase of +0.16 (2.13%)
As of 04/30/2025 05:00 PM ET

This chart shows the closing price history over time for FOLD up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
JunJulAugSepOctNovDecJanFebMarApr$7.52Closing price on 04/29/25:

SEC Filings (Institutional Ownership Changes) for Amicus Therapeutics (NASDAQ:FOLD)

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at FOLD by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$1.17Mbought$2.34MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100M$0$100MTotal InflowsTotal Outflows
Amicus Therapeutics logo
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Read More on Amicus Therapeutics

Today's Range

Now: $7.68
Low: $7.37
High: $7.71

50 Day Range

MA: $8.08
Low: $6.48
High: $9.49

52 Week Range

Now: $7.68
Low: $6.20
High: $12.65

Volume

4,493,430 shs

Average Volume

2,643,874 shs

Market Capitalization

$2.36 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.79

Who are the company insiders with the largest holdings of Amicus Therapeutics?

Amicus Therapeutics' top insider shareholders include:
  1. Bradley L Campbell (CEO)
  2. John F Crowley (Chairman)
  3. Ellen Rosenberg (Insider)
  4. Jeff Castelli (Insider)
  5. David Michael Clark (Insider)
  6. Samantha Prout (CAO)
  7. Margaret G Mcglynn (Director)
Learn More about top insider investors at Amicus Therapeutics.

Who are the major institutional investors of Amicus Therapeutics?

Amicus Therapeutics' top institutional investors include:
  1. Bank of New York Mellon Corp — 0.32%
  2. Peregrine Capital Management LLC — 0.30%
  3. Rhumbline Advisers — 0.14%
  4. Envestnet Asset Management Inc. — 0.06%
  5. Wedge Capital Management L L P NC — 0.05%
  6. SG Americas Securities LLC — 0.03%
Learn More about top institutional investors of Amicus Therapeutics stock.

Which institutional investors are selling Amicus Therapeutics stock?

Within the previous quarter, FOLD stock was sold by these institutional investors:
  1. Envestnet Asset Management Inc.
  2. Wedge Capital Management L L P NC
  3. Bank of New York Mellon Corp
  4. Teacher Retirement System of Texas
  5. Vontobel Holding Ltd.
  6. China Universal Asset Management Co. Ltd.
  7. Principal Financial Group Inc.

Which institutional investors are buying Amicus Therapeutics stock?

During the previous quarter, FOLD stock was purchased by institutional investors including:
  1. SG Americas Securities LLC
  2. Peregrine Capital Management LLC
  3. Rhumbline Advisers
  4. Procyon Advisors LLC
  5. Allspring Global Investments Holdings LLC
  6. GAMMA Investing LLC
  7. Diversified Trust Co